Evotec SE/€EVT
1D1W1MYTD1Y5YMAX
Capital at risk
About Evotec SE
Evotec SE is a biotechnology company specializing in drug discovery and development solutions across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. The company provides integrated services and innovative research through its platforms, such as EVOequity and INDiGO, which accelerate drug candidates from discovery to commercialization. Founded in 1993, Evotec is headquartered in Hamburg, Germany, and operates worldwide with multiple research sites in Europe and the United States. Through strategic collaborations with pharmaceutical and academic institutions, Evotec enhances its research capabilities and expands its global reach, leveraging advanced technologies and a collaborative approach to drive innovation in drug development.
- Ticker
- €EVT
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 4,461
- Headquarters
- Hamburg, Germany
- Website
- www.evotec.com
Evotec SE Metrics
BasicAdvanced
€528M
-
-€1.11
1.26
-
Price and volume
Market cap
€528M
Beta
1.26
52-week high
€7.75
52-week low
€2.97
Average daily volume
783K
Financial strength
Current ratio
2.333
Quick ratio
2.023
Long term debt to equity
0.622
Total debt to equity
0.715
Profitability
EBITDA (TTM)
-73.181
Gross margin (TTM)
8.46%
Net profit margin (TTM)
-27.47%
Operating margin (TTM)
-20.33%
Effective tax rate (TTM)
-7.21%
Revenue per employee (TTM)
€160,000
Management effectiveness
Return on assets (TTM)
-5.39%
Return on equity (TTM)
-26.08%
Valuation
Price to revenue (TTM)
0.745
Price to book
0.79
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-3.074
Free cash flow yield (TTM)
-32.53%
Free cash flow per share (TTM)
-0.978
Growth
Revenue change (TTM)
-7.72%
Earnings per share change (TTM)
26.46%
3-year revenue growth (CAGR)
-3.51%
10-year revenue growth (CAGR)
17.08%
3-year earnings per share growth (CAGR)
23.85%
10-year earnings per share growth (CAGR)
39.61%
Bulls say / Bears say
Net sales in Discovery & Preclinical Development ex-strategic partnerships grew by approximately 28% year-on-year in H1 2026, reflecting improved customer engagement and commercial execution (SEC EDGAR EX-99.2).
Just – Evotec Biologics achieved high capacity utilization and expanded its customer base in H1 2026, underpinning stability and growth prospects in its biologics segment (SEC EDGAR EX-99.2).
On August 6, 2026, Evotec entered a strategic AI-enabled R&D collaboration with Odyssey Therapeutics to discover and validate small-molecule drug candidates, unlocking milestone-based revenue potential (Evotec).
Full-year 2026 guidance was cut sharply, with revenues now expected at €570–610 million (previously €700–780 million) and adjusted EBITDA forecast at a €70–105 million loss (versus a prior €0–40 million profit outlook), driven by delayed milestone payments and partnership phasing (SEC EDGAR EX-99.2).
Evotec reported a preliminary operating loss of €42.7 million in H1 2026, underscoring sustained negative EBITDA and ongoing cash burn despite a liquidity buffer of €465.6 million as of June 30, 2026 (SEC EDGAR EX-99.2).
In March 2026, Evotec announced plans to cut up to 800 jobs and close four sites to achieve cost savings, signaling operational strain and potential disruption to its research capabilities (Reuters via Onvista).
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Upcoming events
No upcoming events
Funds containing Evotec SE
AllEURUSDGBP
Fund name | Fund size | €EVT weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 0.38% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.07% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.07% |
iShares Healthcare Innovation£DRDR | £1B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.